<DOC>
	<DOCNO>NCT00532675</DOCNO>
	<brief_summary>This study evaluate safety LBH589 give combination lenalidomide dexamethasone adult patient multiple myeloma</brief_summary>
	<brief_title>Safety Study LBH589 When Given Combination With Lenalidomide Dexamethasone Adult Patients With Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : Patients must diagnosis active multiple myeloma Patients must receive least one prior line therapy disease relapsed.. Patients must suitable treatment lenalidomide &amp; dexamethasone . Adults ≥ 18 year old ECOG Performance Status ≤ 2 Life expectancy &gt; 12 week Patients must acceptable neutrophil platelet count well adequate kidney liver function . Able sign inform consent comply protocol Exclusion criterion : Primary refractory MM Peripheral neuropathy ≥ CTCAE grade 2 Impaired cardiac function clinically significant cardiac disease Impairment GI function GI disease may significantly alter absorption LBH589 Patients diarrhea &gt; CTCAE grade 1 Patients use medication relative risk prolong QT interval Concomitant use CYP3A4 inhibitor Patients history deep vein thrombosis thromboembolism within &lt; 6 month prior start study treatment Patients undergone major surgery ≤ 4 week prior start study drug recover side effect therapy Women pregnant breast feed woman childbearing potential ( WOCBP ) use 2 reliable form birth control Male patient whose sexual partner WOCBP unable use latex condom sexual contact ( even undergone vasectomy ) Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>LBH589</keyword>
	<keyword>Combination</keyword>
</DOC>